14 completed, 12 recruiting, 6 terminated, 3 unknown. 11 Phase 2, 8 Phase 3, 6 Not applicable, 2 Phase 1, 2 Phase 4.
Follow Chronic Inflammatory Demyelinating Polyneuropathy: new trials by email Literature Review of Chronic Inflammatory Demyelinating Polyneuropathy trials Research Report on Chronic Inflammatory Demyelinating Polyneuropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immune globulin (human) 10% solution for intravenous administration - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Kedrion S.p.A. | 161 | 2026-10-01 | 2026-09-11 |
| Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment KITE-363, Fludarabine, Cyclophosphamide - Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis | Phase 1 | Recruiting | Kite, A Gilead Company | 57 | 2026-04-10 | 2026-10-19 |
| Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease Whole-body Electrical Muscle Stimulation Exercise - Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis | Not applicable | Recruiting | University of Missouri-Columbia | 50 | 2026-03-10 | 2026-03-17 |
| A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP Empasiprubart IV, Placebo IV - Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | Phase 3 | Recruiting | argenx | 160 | 2025-09-16 | 2026-10-27 |
| The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period. Assistive gait devices combined with physiotherapy - Inclusion Body Myositis, Myotonic Dystrophy 1 | Not applicable | Enrolling by invitation | LMU Klinikum | 30 | 2025-09-01 | 2025-07-18 |
| An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Batoclimab - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Immunovant Sciences GmbH | 26 | 2025-08-28 | 2026-08-11 |
| Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | University of Ulm | 140 | 2025-08-27 | 2025-09-11 | |
| A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP empasiprubart, IVIg, empasiprubart-placebo - Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | Phase 3 | Recruiting | argenx | 218 | 2025-08-22 | 2026-10-30 |
| Vitaccess Real CIDP Registry Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | Not yet recruiting | Vitaccess Ltd | 300 | 2025-07-31 | 2025-06-05 | |
| Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy Rituximab - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Withdrawn | University of Kansas Medical Center | 2025-07-01 | 2025-09-17 | |
| Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP NVG-2089 - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Nuvig Therapeutics, Inc. | 14 | 2025-04-25 | 2026-10-06 |
| Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Imeroprubart, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Recruiting | Immunovant Sciences GmbH | 162 | 2025-03-18 | 2026-09-30 |
| A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) Claseprubart, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Dianthus Therapeutics | 256 | 2025-02-10 | 2026-10-28 |
| A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC Efgartigimod PH20 SC - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 4 | Completed | argenx | 23 | 2024-12-10 | 2026-04-06 |
| Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders FBIndex - Inclusion Body Myositis, Myotonic Dystrophy | Enrolling by invitation | LMU Klinikum | 108 | 2024-09-09 | 2025-09-10 | |
| A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) riliprubart, Placebo, IVIg - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Sanofi | 160 | 2024-08-21 | 2026-10-19 |
| Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility. Actimyo - Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | Centre Hospitalier Universitaire de Liege | 40 | 2023-08-28 | 2025-02-12 | |
| RWE-based Treatment Patterns and Outcomes in CIDP No intervention. Retrospective observation only. - Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome | Unknown | RwHealth | 170 | 2023-08-17 | 2023-07-11 | |
| Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy Chronic Inflammatory Demyelinating Polyneuropathy | Not yet recruiting | Assiut University | 36 | 2023-01-01 | 2022-02-02 | |
| To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Immunovant Sciences GmbH | 94 | 2022-12-15 | 2026-08-11 |
Showing 20 of 44. Sign in to see all of them.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (44) · Autoimmune Diseases (4) · Charcot-Marie-Tooth Disease (4) · Lambert-Eaton Myasthenic Syndrome (4) · Muscular Atrophy, Spinal (4) · Muscular Dystrophy, Facioscapulohumeral (4) · Myasthenia Gravis (4) · Glycogen Storage Disease Type II (3) · Guillain-Barre Syndrome (3) · Myositis, Inclusion Body (3) · Myotonic Dystrophy (3) · Neuromuscular Diseases (3) · Peripheral Nervous System Diseases (3) · Amyotrophic Lateral Sclerosis (2) · Diabetes Mellitus (2)
Chronic Disease (44) · Demyelinating Diseases (44) · Disease Attributes (44) · Pathologic Processes (44) · Pathological Conditions, Signs and Symptoms (44) · Polyneuropathies (44) · Autoimmune Diseases of the Nervous System (43) · Immune System Diseases (43) · Nervous System Diseases (43) · Polyradiculoneuropathy (43) · Neuromuscular Diseases (41) · Peripheral Nervous System Diseases (41) · Autoimmune Diseases (40) · Neurodegenerative Diseases (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8)
Immunoglobulins, Intravenous (8) · Hizentra (4) · Cyclophosphamide (2) · Immunoglobulins (2) · Injections, Subcutaneous (2) · Administration, Intravenous (1) · Antilymphocyte Serum (1) · Biotin (1) · Carmustine (1) · Cytarabine (1) · Etoposide (1) · Hematopoietic Stem Cell Transplantation (1) · Melphalan (1) · Peripheral Blood Stem Cell Transplantation (1) · Physical Therapy Modalities (1)
CSL Behring (4) · Immunovant Sciences GmbH (3) · argenx (3) · LMU Klinikum (2) · Assiut University (1) · Centre Hospitalier Universitaire de Liege (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dianthus Therapeutics (1) · Emory University (1) · First Affiliated Hospital of Fujian Medical University (1) · Fred Hutchinson Cancer Center (1) · Hope Biosciences Research Foundation (1) · Kedrion S.p.A. (1) · Kite, A Gilead Company (1) · Mamatha Pasnoor, MD (1)
United States (25) · Germany (11) · France (10) · Belgium (8) · Italy (8) · Poland (8) · United Kingdom (8) · Argentina (7) · Brazil (7) · Denmark (7) · Canada (6) · Greece (6) · Japan (6) · Romania (6) · Spain (6)
Ari Breiner, MD, FRCPC (1) · Djamchid Lotfi, MD (1) · Frederic Sedel, MD (1) · Houman Hemmati, MD (1) · Jau-Shin Lou, MD, PhD (1) · Jeffrey A Allen, MD (1) · Johannes Dorst (1) · Johannes Jakobsen, DMSc (1) · Lakshmi Deshpande (1) · Leona Holmberg (1) · Luigi Brunetti, PhD (1) · Mamatha Pasnoor, MD (1) · Margaux Poleur, Dr (1)
PMID 12084892, PMID 15703014, PMID 16267188, PMID 16849828, PMID 16900450, PMID 22003934, PMID 23781960, PMID 24858016, PMID 27455854, PMID 28168524, PMID 28594116, PMID 28768822, PMID 28881389, PMID 29122523, PMID 32594300, PMID 33593867, PMID 37899433, PMID 40189914, PMID 42578463
2009 (1), 2023 (1), 2025 (1)